Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.0252W HIGH $0.29
Volume
112.71 K
Value Traded
11.47 K
Short % Float
0%
Days to Cover
1.0
-17.33%Week
-24.56%1 Month
-29.82%3 Month
+5.22%6 Month
-98.79%5 Year
-98.84%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.89 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
0.00%
Institutions
0.00%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
GRTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Galera Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How GRTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-08-10 | Avasopasem manganese (GC4419) | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every GRTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| avasopasem Priority | radiotherapy-induced severe oral mucositis | Phase 3 | 2022-10-26 | chronic kidney disease reduced by 50%; n=551Read More | Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting Tumor outcomes and overall survival maintained in patients with HNC at one-yeRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sorensen MelDirector, Officer (President and CEO) | Sell | -70,000 195,029 held | $0.02 | 11/20/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in GRTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 0 % | 448.37 K | 3.08 M |
Ownership Trends
GRTX Short Interest
Shares sold short, counted twice a month.
0%
Short % of Float
of tradable shares sold short
7.4K
Shares Sold Short
+9.6% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
241.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GRTX ranks across every disease it competes in
Competitive Position is a premium feature
See how GRTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGRTX News
About Galera Therapeutics, Inc.
Founded07-11-2019
BIOPHARMAWATCH ELITE PLUS
Trade the next GRTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime